Ollin Refuels with $330M to Back Pivotal Tests of Vabysmo Challenger

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors

Ollin raises $330 million to fund late-stage eye disease drug trials

Bispecific antibody firm Ollin raises $330m in bumper round

Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.

Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026

AUSTIN, Texas--(BUSINESS WIRE)--Jun 24, 2026-

Ophthalmology venture grabs investors’ attention, raises $330 million

The company, which is developing treatments for eye diseases, has raised $330 million from investors as it readies for late-stage testing.

Ollin refuels with $330M to back pivotal tests of Vabysmo challenger

One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.